|Awarded On||August 20, 2014|
|Title||Opening the Central Nervous System to Immunotherapy by Blocking TREK1|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Michael Curran|
|Cancer Sites||Brain and Other Nervous System|
To maintain the integrity of the brain and central nervous system, the body maintains a blood-brain barrier which blocks many drugs and compounds as well as potentially destructive elements of the host’s own immune system from crossing. Although beneficial in most instances, in the setting of primary or metastatic cancer of the brain this barrier acts to block the immune system from attacking these tumors by denying access. For corporeal cancers such as melanoma, restoring the capacity of the immune system to attack and destroy cancers, a treatment known as immunotherapy, has shown the capacity to eliminate previously untreatable, metastatic tumors. Immunotherapy has given new hope of long-t...